Plain-English translation of NCT06351605 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a treatment called photobiomodulation (PBM), which uses specific wavelengths of light delivered through a device called the Valeda Light Delivery System to treat dry age-related macular degeneration—a condition that causes progressive vision loss in older adults. Researchers want to learn whether this light-based treatment is safe and whether it can help slow the progression of vision loss in people with this condition.
Dry age-related macular degeneration is a common cause of vision loss in older people, and current treatment options are limited. This study aims to see if this medication offers a new, non-invasive way to help protect vision and slow disease progression.
You likely qualify if…
You likely don't qualify if…
You will receive nine short light therapy treatments over three to five weeks using the Valeda Light Delivery System, which delivers specific wavelengths of light to your eye in brief sessions. After this initial round, you may receive up to five additional rounds of treatment every four to six months, depending on how your condition progresses and what your doctor recommends. Your total involvement could last up to 31 months, with eye imaging (OCT scans) performed after each treatment round to monitor your vision and response to the therapy.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States